Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 145
    Published on February 26, 2017


Risks To Heart Health In Women

One out of every three deaths in women is due to cardiovascular disease in the United States. Deaths are more in women compared with men. Coronary heart disease, high blood pressure, cerebrovascular disease, peripartum cardiomyopathy, peripheral vascular disease and congestive heart failure diseases come under the category of cardiovascular diseases. Risk factors for cardiovascular disease specific to women are

Sometimes women may experience unrecognized symptoms of cardiovascular diseases such as fatigue, heartburn and shortness of breath. Daily exercise and proper diet reduces cholesterol and blood pressure levels and causes a reduction in risk of cardiovascular disease.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Heart Trouble Later In The Life For Women With Preterm Delivery
2. Babies Born To Diabetic Mother Often Bigger
3. Wearable Devices Market
4. Wearable Belt Type Medical Device To Treat Diabetes In Obese Individuals

 

Stillbirth : Delivery of dead baby after surviving for at least 28 weeks of pregnancy is called stillbirth.

 

Seven Heart Healthy Habits

Deaths due to heart disease is a leading cause of death in spite of increasing awareness of the risk factors. Experts say lives and medical costs could be saved if people follow at least 5 out of 7 following heart-healthy habits with decreased health risks

  • No cigarette smoking
  • Performing physical activity
  • Following healthy diet
  • Keeping body mass index (BMI) within limits
  • Keeping blood pressure (BP) within limits
  • Keeping cholesterol levels within limits
  • Keeping blood sugar or glucose levels within limits

The study findings were published in the Journal of the American Heart Association Circulation



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Benefits With Eating Healthy Fats
2. Chameleon Wearable Fitness Tracker From Adidas
3. Portable Device To Check Diabetes With Exhale Of Acetone Chemical
4. Curing Hepatitis C Reduces The Risk Of Kidney Failure

 

 

About ITCA 650 Type 2 Diabetes Drug

Intarcia Therapeutics, manufacturers of ITCA 650, a new type 2 diabetes drug have announced that their New Drug Application (NDA) was accepted by FDA for active review.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. About ITCA 650
2. Portable Type 1 And Type 2 Diabetes Tester
3. Wearable Technology For Elder Care
4. About Esysta device

 

 

VERTIS MONO Trial Of Ertugliflozin SGLT2 Monotherapy For Type 2 Diabetes Patients

Ertugliflozin is a type ii diabetes drug (T2D) for adults. This drug works by blocking SGLT2 protein belonging to kidneys. SGLT2 protein injects filtered blood glucose or sugar collected by kidneys back into the bloodstream. As the ertugliflozin drug blocks SGLT2 protein function, more glucose or sugar will be removed from blood via urine by kidneys. Studies show improved A1C control in adult type 2 diabetes (T2D) patients. Latest VERTIS MONO trial results for ertugliflozin, a SGLT2 inhibitor jointly developed by Merck and Pfizer published in the journal Diabetes shows improved A1C control, 4 to 4.5 pounds of weight loss and lower blood pressure (or hypertension) in adult patients with type 2 diabetes (T2D). 461 type ii diabetes (T2D) individuals participated in this VERTIS MONO trial. Following applications along with study results were filed for drug approval

  • Ertugliflozin as a monotherapy
  • Fixed dose combination with metformin
  • Fixed dose combination with sitagliptin (Januvia)

Update


FDA approved SGLT2 Steglatro (Ertugliflozin) drug for type 2 diabetes patients from Merck and Pfizer.

Ertugliflozin oral drug was approved by the FDA on December 20, 2017. This drug will be sold under the brand name Steglatro. Other SGLT2 inhibitors similar to ertugliflozin were

  • Farxiga from AstraZeneca Plc
  • Jardiance from Eli Lilly and Boehringer Ingelheim
  • Invokana from Johnson & Johnson


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. SGLT2 Inhibitor Drug Ertugliflozin
2. SGLT1 and SGLT2 Inhibitor Sotagliflozin Drug Trials
3. Consumption Of Meat Contributes Development Of Type 2 Diabetes
4. Access Crosby Wearable Fitness Tracking Products From Michael Kors

 

 

Improved Mortality Among Older Type 2 Diabetes Individuals With Metformin

A study done by researchers from the University of Texas Health Science Center, San Antonio, United States shows improved mortality in more than 65 years old type ii diabetes (T2D) patients. The study shows prevention of diseases such as cancer, depression, cardiovascular disease and dementia. Risk reduction varies according to individual's risk among diabetes patients. The researchers concluded that further studies are required to find out the role of metformin. One of the participants in the study was Chen-Pin Wang PhD and the study findings were published online in the Journal of Diabetes and its Complications.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Breast Development Linked To Type 2 Diabetes
2. Updated Guidelines Reaffirms Faith In Metformin
3. About Meizus H1 Wearable Device
4. Wearable Device To Alleviate Stress and Anxiety

 

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.